These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. González MA; Straughan AB Clin Ther; 1994; 16(5):804-14. PubMed ID: 7859239 [TBL] [Abstract][Full Text] [Related]
4. Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men. Dockhorn RJ; Cefali EA; Straughn AB Ann Allergy; 1994 Mar; 72(3):218-22. PubMed ID: 8129214 [TBL] [Abstract][Full Text] [Related]
5. Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. Rojanasthien N; Kovjiriyapan K; Manorot M; Pothirat C Asian Pac J Allergy Immunol; 2001 Jun; 19(2):69-78. PubMed ID: 11699723 [TBL] [Abstract][Full Text] [Related]
6. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels. Steinijans VW; Zech K; Fischer R Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100 [TBL] [Abstract][Full Text] [Related]
7. Steady-state pharmacokinetics of a once-daily theophylline formulation (Euphylong) when given twice daily. Götz J; Sauter R; Steinijans VW; Jonkman JH Int J Clin Pharmacol Ther; 1994 Apr; 32(4):168-73. PubMed ID: 8032575 [TBL] [Abstract][Full Text] [Related]
8. Variations in absorption of theophylline from two sustained-release products. Ferrari M; Olivieri M; Barozzi E; Ramponi C Clin Ther; 1986; 8(6):646-54. PubMed ID: 3791362 [TBL] [Abstract][Full Text] [Related]
9. Once-a-day dosing with theophylline: a comparison of four sustained-release products. Minotti DA; Altman LC; Ayars GH; Popick FR; Benn VJ Ann Allergy; 1992 Jun; 68(6):500-6. PubMed ID: 1610026 [TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of Theophylline (CAS No. 58-55-9) in F344/N Rats and B6C3F1 Mice (Feed and Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1998 Aug; 473():1-326. PubMed ID: 12571677 [TBL] [Abstract][Full Text] [Related]
11. Theophylline absorption from two sustained-release products. Implications for therapeutic drug monitoring. Rogers RJ; Wiener MB; Hill MR; Szefler SJ Am Rev Respir Dis; 1987 Nov; 136(5):1168-73. PubMed ID: 3674579 [TBL] [Abstract][Full Text] [Related]
13. Effect of once daily and twice daily sustained release theophylline formulations on daytime variation of bronchial hyperresponsiveness in asthmatic patients. Ferrari M; Olivieri M; Lampronti G; Bonazza L; Biasin C; Nacci P; Talamini G; Lo Cascio V Thorax; 1997 Nov; 52(11):969-74. PubMed ID: 9487345 [TBL] [Abstract][Full Text] [Related]
14. Sustained-release theophylline. Pharmacokinetic and therapeutic comparison of two preparations. Menendez R; Kelly HW; Howick J; McWilliams BC Am J Dis Child; 1983 May; 137(5):469-73. PubMed ID: 6846276 [TBL] [Abstract][Full Text] [Related]
15. Absorption of sustained-release theophylline tablets. Fagerström PO; Heintz L Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):359-62. PubMed ID: 6885207 [TBL] [Abstract][Full Text] [Related]
16. Absorption of theophylline from conventional and sustained-release tablets. Mellstrand T; Svedmyr N; Fagerström PO Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088 [TBL] [Abstract][Full Text] [Related]
17. Bioavailability of a slow-release theophylline capsule given twice daily to preschool children with chronic asthma: comparison with liquid theophylline. Sallent J; Hill M; Stecenko A; McKenzie M; Hendeles L Pediatrics; 1988 Jan; 81(1):116-20. PubMed ID: 3336577 [TBL] [Abstract][Full Text] [Related]
18. Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur. Takagi K; Hasegawa T; Ogura Y; Yamaki K; Suzuki R; Satake T; Imaeda N; Mizukami Y Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):530-5. PubMed ID: 3429057 [TBL] [Abstract][Full Text] [Related]
19. Theophylline QID, TID, BID and now QD? A report on 24-hour dosing with slow-release theophylline formulations with emphasis on analyses of data used to obtain Food and Drug Administration approval for Theo-24. Weinberger MM Pharmacotherapy; 1984; 4(4):181-98. PubMed ID: 6483637 [TBL] [Abstract][Full Text] [Related]
20. Bioequivalence of a generic slow-release theophylline tablet in children. Kanthawatana S; Ahrens RC; McCubbin M; Bronsky E; Blake K; Hendeles L J Pediatr; 1994 Dec; 125(6 Pt 1):987-91. PubMed ID: 7996375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]